Navigation Links
Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018
Date:5/31/2011

NEW YORK, May 31, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018

http://www.reportlinker.com/p0512284/Global-Market-for-Hormonal-Contraceptives-and-Infertility-Drugs-2011-2018.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Provides analysis of over ten key marketed products and indentifies over 40 R&D candidates in preclinical to clinical stages of development.

Future Therapies for Birth Control and Reproductive Health

The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.

In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health  (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Key findings of the report include

-The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.

-Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.

-Currently, there are over 40 pipeline candidates for female and male contraception.

-The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.

-Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.  

-Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.

-The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.

Questions answered by this report include:

-Which contraceptives and infertility drugs are the current and potential future market leaders 

-What impact new drug approvals will have on the reproductive medicine drug market

-Which premarket drugs are identified as high-value products

-Which companies are developing hormonal contraceptives and infertility drugs

-Sales predictions to 2018 for leading contraceptives and infertility drugs  

-How will newcomers affect the product positioning of market leaders  

-What are niche market opportunities in reproductive medicine

-What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies

-How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders

-Which molecules and compounds are main R&D clusters in reproductive medicine     

Research Methodology

The contents of this URCH Publishing report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:

-Company information

-Scientific periodicals

-Personal communication

-Product information

-Trade press articles

-Market analyst data

-News releases                             

-Public information datasets

-Internet-based research

-Conference proceedings

-Library research         

-Medical/pharma associations

Table of Contents

Executive Summary

Report Highlights

Objectives of the Report

1. Contraception and Infertility: Market Snapshot

Market data synopsis - contraception and infertility

1.1 Reproductive Health Market Overview

1.2 Market Analysis for Contraception and Infertility

1.2.1 Contraception

1.2.2 Infertility

2. Product Market for Hormonal Contraception

2.1 Contraceptive Formulations

2.2 Combined Estrogen-Progestogen Contraceptives

2.3 Progestogen-Only Contraceptives

2.4 Product Market for Hormonal Contraceptives

2.4.1 Bayer Healthcare Pharmaceuticals

2.4.1.1 Key Product and Portfolio Review

2.4.1.2  Pipeline Focus

Contraceptive Patch

Intrauterine device

2.4.1.3  Sales Estimates and Product Market Outlook

2.4.2  Johnson & Johnson

2.4.2.1  Key Product and Portfolio Review

2.4.2.2 Sales Forecasts and Product Market Outlook

2.4.3 Merck & Co

2.4.3.1 Key Product and Portfolio Review

2.4.3.2 Sales Estimates and Product Market Outlook

2.4.4 Pfizer

2.4.4.1 Key Product and Portfolio Review

2.4.4.2 Sales Estimates and Product Market Outlook

2.4.5 Teva Pharmaceutical Industries

2.4.5.1 Key Product and Portfolio Review

2.4.5.2 Pipeline Focus

2.4.5.3 Sales Estimates and Product Market Outlook

Generics Focus - Watson Pharmaceuticals

2.5 Future Considerations and Outlook for the Contraceptive Product Market

3. Product Market for Infertility Drugs

3.1 Overview for Infertility Drugs

3.2 Pharmacotherapies for Infertility

Mechanism of Action of Infertility Pharmacotherapeutics

3.3 Product Market for Infertility Drugs

3.3.1 AstraZeneca

3.3.1.1. Key Product Review

3.3.1.2 Sales Estimates and Product Market Outlook

3.3.2 Ferring

3.3.2.1 Key Product and Portfolio Review

3.3.2.2. Sales Estimates and Product Market Outlook

3.3.3 Merck & Co

3.3.3.1 Key Product and Portfolio Review

3.3.4 Merck Serono

3.3.4.1 Key Product and Portfolio Review

3.3.4.2 Sales Estimates and Product Market Outlook

3.4 Market Outlook for Infertility Pharmacotherapeutics

4. Research and Development in Reproductive Health

4.1 Female Oral Contraception

4.1.1 Transdermal/Transmucosal Contraceptives

4.1.2 Implantable/Injectable Contraceptives

4.2 Male Contraception

4.3 Contraception - Research and Development Overview

4.4 Infertility Drugs in Research and Development

4.4.1 Female Infertility

4.4.2 Male Infertility

6.3.2.1 Infertility - Research and Development Overview

Reference Sources

List of Tables

Research Methodology

Table 1.1 Estimated Global Sales (US$m) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018

Table 2.1 Selection of Hormonal Contraceptives Segmented by Formulation and Delivery Route, 2011

Table 2.2 Bayer's Hormonal Contraceptive Product Portfolio, 2011

Table 2.3 Bayer`s Pipeline Contraceptive Candidates, 2011

Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Bayer's Leading Hormonal Contraceptive Products, 2011-2018

Table 2.5 Johnson & Johnson`s Hormonal Contraceptive Product Portfolio, 2011

Table 2.6 Estimated Sales (US$m) and Annual Growth (%) of Johnson & Johnson`s Leading Hormonal Contraceptive Products, 2011-2018

Table 2.7 Merck & Co's Hormonal Contraceptive Product Portfolio, 2011

Table 2.8 Estimated Sales (US$m) and Annual Growth (%) of Merck & Co's Leading Hormonal Contraceptive Products, 2011-2018

Table 2.9 Pfizer`s Hormonal Contraceptive Product Portfolio, 2011

Table 2.10 Estimated Sales (US$m) and Annual Growth (%) of Pfizer`s Leading Hormonal Contraceptive Products, 2011-2018

Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011

Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011 (continued)

Table 2.12 Estimated Sales (US$m) and Annual Growth (%) of Teva`s Leading Hormonal

Table 3.1 Pharmacotherapies for Infertility, 2011

Table 3.2 Ferring`s Infertility Product Portfolio, 2011

Table 3.3 Estimated Global Sales (US$m) and Annual Growth (%) of Ferring`s Infertility Products, 2011-2018

Table 3.4 Merck & Co.`s Hormonal Infertility Product Portfolio, 2011

Table 3.5 Estimated Global Sales (US$m) and Annual Growth (%) of Merck & Co.'s Hormonal Infertility Products, 2011-2018

Table 3.6 Merck Serono`s Hormonal Infertility Product Portfolio, 2011

Table 3.7 Estimated Global Sales (US$m) and Annual Growth (%) of Merck Serono`s Hormonal Infertility Products, 2011-2018

Table 4.1 Female Oral Contraceptives in Development, 2011

Table 4.1 Female Oral Contraceptives in Development, 2011 (continued)

Table 4.2 Transdermal/Transmucosal Female Contraceptives in Development, 2011

Table 4.3 Implantable/Injectable Female Contraceptives in Development, 2011

Table 4.4 Male Contraceptives in Development, 2011

Table 4.5 Drugs in Development for Female Infertility, 2011

Table 4.6 Drugs in Development for Male Infertility, 2011 

List of Figures

Figure 1.1 Estimated Sales (US$m) and Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018

Figure 1.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2011 & 2018

Figure 2.1 Global Revenue Trends for Bayer's Leading Hormonal Contraceptive Products, 2005-2010

Figure 2.2 Global Revenue Trends for Johnson & Johnson's Leading Hormonal Contraceptive Products, 2005-2010

Figure 2.3 Global Revenue Trends for Merck & Co's Leading Hormonal Contraceptive Products, 2005-2010

Figure 2.4 Global Product Sales for Pfizer's Hormonal Contraceptive Franchise, 2005-2010

Figure 2.5 Global Sales Trends of Teva's Leading Hormonal Contraceptive Products, 2005-2010

Figure 2.6 Leading Hormonal Contraceptive Products by Sales Revenue (US$m), 2011 (estimated)

Figure 3.1 Global Sales Trends of Merck & Co.'s Leading Hormonal Infertility Products, 2005-2010

Figure 3.2 Global Sales Trends of Merck Serono's Leading Hormonal Infertility Products,

Figure 3.3 Leading Hormonal Infertility Products by Sales Revenue (US$m), 2011 (estimated)

To order this report:

Drug and Medication Industry: Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
Breaking Medicine News(10 mins):